Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study
Open Access
- 4 December 2020
- journal article
- research article
- Published by Springer Nature in BMC Molecular and Cell Biology
- Vol. 21 (1) , 1-13
Abstract
Background: Type A influenza viruses are contagious and even life-threatening if left untreated. So far, no broadly protective vaccine is available due to rapid antigenic changes and emergence of new subtypes of influenza virus. In this study, we exploited bioinformatics tools in order to design a subunit chimeric vaccine from the antigenic and highly conserved regions of HA and M2 proteins of H7N9 subtype of influenza virus. We used mucosal adjuvant candidates, including CTxB, STxB, ASP-1, and LTB to stimulate mucosal immunity and analyzed the combination of HA2, M2e, and the adjuvant. Furthermore, to improve the antigen function and to maintain their three-dimensional structure, 12 different linkers including six rigid linkers and six flexible linkers were used. The 3D structure model was generated using a combination of homology and ab initio modeling methods and the molecular dynamics of the model were analyzed, either. Results: Analysis of different adjuvants showed that using CtxB as an adjuvant, results in higher overall vaccine stability and higher half-life among four adjuvant candidates. Fusion of antigens and the CTxB in the form of M2e-linker-CTxB-linker-HA2 has the most stability and half life compared to other combination forms. Furthermore, the KPKPKP rigid linker showed the best result for this candidate vaccine among 12 analyzed linkers. The changes in the vaccine 3D structure made by linker insertion found to be negligible, however, although small, the linker insertion between the antigens causes the structure to change slightly. Eventually, using predictive tools such as Ellipro, NetMHCpan I and II, CD4episcore, CTLpred, BepiPred and other epitope analyzing tools, we analyzed the conformational and linear epitopes of the vaccine. The solubility, proteasome cleavage sites, peptidase and potential chemical cutters, codon optimization, post translational modification were also carried out on the final vaccine. Conclusions: It is concluded that M2e-Linker-CTxB-Linker-HA2 combination of chimeric vaccine retains its 3D structure and antigenicity when KPKPKP used as linker and CTxB used as adjuvant.Keywords
Funding Information
- Iran University of Medical Sciences (14087)
This publication has 40 references indexed in Scilit:
- Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic PreparednessPLOS ONE, 2013
- The Mucosal Adjuvant Cholera Toxin B Instructs Non-Mucosal Dendritic Cells to Promote IgA Production Via Retinoic Acid and TGF-βPLOS ONE, 2013
- The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human PrimatesPLOS ONE, 2012
- Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvantVaccine, 2010
- Bimodal protein solubility distribution revealed by an aggregation analysis of the entire ensemble of Escherichia coli proteinsProceedings of the National Academy of Sciences, 2009
- Prospects for Universal Influenza Virus VaccineEmerging Infectious Diseases, 2006
- 1918 Influenza: the Mother of All PandemicsEmerging Infectious Diseases, 2006
- 1918 Influenza: the Mother of All PandemicsEmerging Infectious Diseases, 2006
- Influenza Pandemics of the 20th CenturyEmerging Infectious Diseases, 2006
- Use of recombinant mammalian cell lines for vaccine productionVaccine, 1984